Diagnostic Accuracy of MRI, Diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma

Barts & The London NHS Trust7 sites in 1 country162 target enrollmentJune 2012

ConditionsSurgically Staged Endometrial and Cervical Carcinoma Cervical Cancer: Invasive Disease, FIGO Stage 1B1 or Higher Endometrial Cancer Stage 1A With Myometrial Invasion or Any Higher Stage and Grade 3 Stage 1A With Myometrial Invasion or Any Other Higher Stage and Serous Papillary or Clear Cell Sub-types Stage II Disease or Above and Any Histology Grade

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Surgically Staged Endometrial and Cervical Carcinoma
Sponsor: Barts & The London NHS Trust
Enrollment: 162
Locations: 7
Primary Endpoint: Detection rate (DR) vrs false positive rate (FPR) for each of the diagnostic modalities.
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a prospective diagnostic performance study which compares three new imaging methods with the current standard imaging method for the diagnosis of metastatic lymph nodes.

Detailed Description

The aim is to demonstrate whether leading edge molecular imaging technologies (FDG-PET/CT, DW-MRI and Fluoro-ethyl-choline (FEC) PET/CT) can identify lymph node metastases with sufficient accuracy to allow non-invasive lymph node staging in patients with endometrial and cervical carcinoma.

Registry

clinicaltrials.gov

Start Date

June 2012

End Date

December 2018

Last Updated

6 years ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

Barts & The London NHS Trust

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Females 18 years or older; (no upper limit).
•Patients with histologically confirmed cancer of the cervix or endometrium.
•In patient with cervix cancer, there must be confirmation of invasive disease; FIGO stage 1B1 or higher FIGO stage demonstrated clinically and/or on MRI. In patients with advanced disease being considered for chemoradiotherapy treatment, patients may be considered for entry if nodal lymphadenectomy is being used to inform radiotherapy planning;
•In patients with endometrial cancer, a) stage 1A with myometrial invasion or any higher stage and grade 3 b) stage 1A with myometrial invasion or any other higher stage and serous papillary or clear cell sub-types
•stage II disease or above and any histology grade The MDT decision may be based on the combination of tumour characteristics on histology, clinical and imaging findings.
•No contra-indication to FDG-PET/CT, FEC-PET/CT or MRI.
•Fit for surgical lymphadenectomy, as determined by the local MDT. The patient should also be considered fit for extended field radiotherapy in cases where lymphadenectomy is being undertaken to inform radiotherapy planning.
•The extent of lymph node dissection will be made by the local multidisciplinary team, based on the presence of risk factors for lymph node metastases, according to the protocol. Patients must be considered fit to undergo lymph node dissection.
•Able and willing to give written informed consent and to comply with the study protocol procedures

Exclusion Criteria

•Known contra-indication to MRI or PET/CT scan.
•Known allergy to FDG or FEC.
•Not considered fit for lymphadenectomy (open or laparoscopic) or, where appropriate, radiotherapy, as determined by the local MDT.
•If the patient is pregnant or breast-feeding.
•Females of childbearing potential must be willing to use an effective method of contraception (hormonal or barrier method of birth control) from the time consent is signed until 6 weeks after the last PET/CT scan unless undergoing hysterectomy.
•Note: subjects are not considered of childbearing potential if they are surgically sterile (they have undergone bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal
•Females of childbearing potential must have a negative pregnancy test within three weeks prior to being registered for the study.
•Participation in another Clinical Trial of an Investigational Medicinal Product (CTIMP). If patient's have recently completed a CTIMP trial they must have had their last dose(s) of study drug prior to their first imaging procedure on the MAPPING study.
•Participation in another clinical trial (CTIMP or non-CTIMP) where the protocol contains imaging procedures that would occur during the MAPPING study.
•Medical or psychiatric illness, which makes the patient unsuitable or unable to give informed consent.

Outcomes

Primary Outcomes

Detection rate (DR) vrs false positive rate (FPR) for each of the diagnostic modalities.

Time Frame: 36 months

Secondary Outcomes

Nodal Coverage planning: standard radiotherapy planning vrs DW-MRI(36 months)
Histopathological findings vrs functional imaging findings(36 months)
Detection rate (DR) vrs false positive rate (FPR) between each of the diagnostic modalities and within different histological sub-sets.(36 months)